BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

• Main Authors: Jing-dong Zhou (Author), Ting-juan Zhang (Author), Zi-jun Xu (Author), Yu Gu (Author), Ji-chun Ma (Author), Xi-xi Li (Author), Hong Guo (Author), Xiang-mei Wen (Author), Wei Zhang (Author), Lei Yang (Author), Xing-hui Liu (Author), Jiang Lin (Author), Jun Qian (Author)
• Format: Book
• Published: BMC, 2019-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background BCL2 protein inhibitor venetoclax (ABT-199) has been authorized by Food and Drug Administration for relapsed/refractory chronic lymphoid leukemia with 17p deletion. Although venetoclax/ABT-199 also caused cell death in acute myeloid leukemia (AML), whether it could be applied to...